SEC Form 4 · accession 0001104659-18-067546

Amphastar Pharmaceuticals, Inc. · AMPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and General Counsel · Director

Period of report

Nov 8, 2018

Accepted (ET)

Nov 9, 2018 · 9:52 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001297184

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Nov 8, 2018	M	5,300	$11.79	A	204,805	D
Common Stock	Nov 8, 2018	M	30,901	$10.46	A	235,706	D
Common Stock^F2	Nov 8, 2018	S	36,201	$20.6786	D	199,505	D
Common Stock	Nov 9, 2018	M	16,095	$10.46	A	215,600	D
Common Stock	Nov 9, 2018	S	16,095	$20.99	D	199,505	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F3	$11.79	Nov 8, 2018	M	5,300	D	—	Sep 28, 2020	Common Stock	5,300	0	D
Employee Stock Option (right to buy)^F3	$10.46	Nov 8, 2018	M	30,901	D	—	Jul 13, 2022	Common Stock	30,901	16,095	D
Employee Stock Option (right to buy)^F3	$10.46	Nov 9, 2018	M	16,095	D	—	Jul 13, 2022	Common Stock	16,095	0	D

F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2018.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.99 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3Shares subject to the option are fully vested and immediately exercisable.